Cyndya A Shibao1, Jorge E Celedonio1, Claudia E Ramirez1, Latisha Love-Gregory1, Amy C Arnold1, Leena Choi1, Luis E Okamoto1, Alfredo Gamboa1, Italo Biaggioni1, Naji N Abumrad1, Nada A Abumrad1. 1. Department of Medicine (C.A.S., J.E.C., C.E.R., A.C.A., L.E.O., A.G., I.B.), Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; Department of Medicine (L.L.-G., N.A.A.), Center for Human Nutrition, Washington University School of Medicine, St Louis, Missouri 63110; Department of Biostatistics (L.C.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232; and Department of Surgery (N.N.A.), Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Abstract
CONTEXT: The scavenger receptor CD36 influences the endothelial nitric oxide-cGMP pathway in vitro. Genetic variants that alter CD36 level are common in African Americans (AAs), a population at high risk of endothelial dysfunction. OBJECTIVE: To examine if the minor allele (G) of coding CD36 variant rs3211938 (G/T) which reduces CD36 level by approximately 50% influences endothelial function, insulin sensitivity (IS), and the response to treatment with the nitric oxide-cGMP potentiator sildenafil. DESIGN: IS (frequently sampled iv glucose tolerance) and endothelial function (flow mediated dilation [FMD]) were determined in age- and body mass index-matched obese AA women with or without the G allele of rs3211938 (protocol 1). Effect of chronic sildenafil treatment on IS and FMD was tested in AA women with metabolic syndrome and with/without the CD36 variant, using a randomized, placebo-controlled trial (protocol 2). SETTING: Two-center study. PARTICIPANTS: Obese AA women. INTERVENTION: A total of 20-mg sildenafil citrate or placebo thrice daily for 4 weeks. MAIN OUTCOME: IS, FMD. RESULTS: G allele carriers have lower FMD (P = .03) and cGMP levels (P = .01) than noncarriers. Sildenafil did not improve IS, mean difference 0.12 (95% confidence interval [CI], -0.33 to 0.58; P = .550). However, there was a significant interaction between FMD response to sildenafil and rs3211938 (P = .018). FMD tended to improve in G carriers, 2.9 (95% CI, -0.9 to 6.8; P = .126), whereas it deteriorated in noncarriers, -2.6 (95% CI, -5.1 to -0.1; P = .04). CONCLUSIONS: The data document influence of a common genetic variant on susceptibility to endothelial dysfunction and its response to sildenafil treatment.
RCT Entities:
CONTEXT: The scavenger receptor CD36 influences the endothelial nitric oxide-cGMP pathway in vitro. Genetic variants that alter CD36 level are common in African Americans (AAs), a population at high risk of endothelial dysfunction. OBJECTIVE: To examine if the minor allele (G) of coding CD36 variantrs3211938 (G/T) which reduces CD36 level by approximately 50% influences endothelial function, insulin sensitivity (IS), and the response to treatment with the nitric oxide-cGMP potentiator sildenafil. DESIGN: IS (frequently sampled iv glucose tolerance) and endothelial function (flow mediated dilation [FMD]) were determined in age- and body mass index-matched obese AA women with or without the G allele of rs3211938 (protocol 1). Effect of chronic sildenafil treatment on IS and FMD was tested in AA women with metabolic syndrome and with/without the CD36 variant, using a randomized, placebo-controlled trial (protocol 2). SETTING: Two-center study. PARTICIPANTS: Obese AA women. INTERVENTION: A total of 20-mg sildenafil citrate or placebo thrice daily for 4 weeks. MAIN OUTCOME: IS, FMD. RESULTS: G allele carriers have lower FMD (P = .03) and cGMP levels (P = .01) than noncarriers. Sildenafil did not improve IS, mean difference 0.12 (95% confidence interval [CI], -0.33 to 0.58; P = .550). However, there was a significant interaction between FMD response to sildenafil and rs3211938 (P = .018). FMD tended to improve in G carriers, 2.9 (95% CI, -0.9 to 6.8; P = .126), whereas it deteriorated in noncarriers, -2.6 (95% CI, -5.1 to -0.1; P = .04). CONCLUSIONS: The data document influence of a common genetic variant on susceptibility to endothelial dysfunction and its response to sildenafil treatment.
Authors: Latisha Love-Gregory; Richard Sherva; Lingwei Sun; Jon Wasson; Timothy Schappe; Alessandro Doria; D C Rao; Steven C Hunt; Samuel Klein; Rosalind J Neuman; M Alan Permutt; Nada A Abumrad Journal: Hum Mol Genet Date: 2008-02-27 Impact factor: 6.150
Authors: Arunima Ghosh; Gurunathan Murugesan; Kan Chen; Li Zhang; Qing Wang; Maria Febbraio; Rita Marie Anselmo; Kandice Marchant; John Barnard; Roy L Silverstein Journal: Blood Date: 2011-04-08 Impact factor: 22.113
Authors: Antoine R Baldassari; Colleen M Sitlani; Heather M Highland; Dan E Arking; Steve Buyske; Dawood Darbar; Rahul Gondalia; Misa Graff; Xiuqing Guo; Susan R Heckbert; Lucia A Hindorff; Chani J Hodonsky; Yii-Der Ida Chen; Robert C Kaplan; Ulrike Peters; Wendy Post; Alex P Reiner; Jerome I Rotter; Ralph V Shohet; Amanda A Seyerle; Nona Sotoodehnia; Ran Tao; Kent D Taylor; Genevieve L Wojcik; Jie Yao; Eimear E Kenny; Henry J Lin; Elsayed Z Soliman; Eric A Whitsel; Kari E North; Charles Kooperberg; Christy L Avery Journal: Circ Genom Precis Med Date: 2020-06-30
Authors: Nada A Abumrad; Ainara G Cabodevilla; Dmitri Samovski; Terri Pietka; Debapriya Basu; Ira J Goldberg Journal: Circ Res Date: 2021-02-04 Impact factor: 17.367
Authors: Vincenza Cifarelli; Stoyan Ivanov; Yan Xie; Ni-Huiping Son; Brian T Saunders; Terri A Pietka; Trevor M Shew; Jun Yoshino; Sinju Sundaresan; Nicholas O Davidson; Ira J Goldberg; Andrew E Gelman; Bernd H Zinselmeyer; Gwendalyn J Randolph; Nada A Abumrad Journal: Cell Mol Gastroenterol Hepatol Date: 2017-01
Authors: Vincenza Cifarelli; Ondrej Kuda; Kui Yang; Xinping Liu; Richard W Gross; Terri A Pietka; Gyu Seong Heo; Deborah Sultan; Hannah Luehmann; Josie Lesser; Morgan Ross; Ira J Goldberg; Robert J Gropler; Yongjian Liu; Nada A Abumrad Journal: Front Cardiovasc Med Date: 2022-08-17